CuraSen appoints Peter Butera as senior vice president of operations

Written by Alan Condon | September 10, 2019 | Print  |

Biotechnology company CuraSen Therapeutics recently appointed Peter Butera as senior vice president of operations.

The company is developing small molecule drugs to treat patients suffering from neurodegenerative diseases such as Parkinson's Disease and Alzheimer's Disease.

Previously, Mr. Butera spent 10 years as director and vice president of clinical operations at Pain Therapeutics. He was also vice president of clinical operations at Attenua and held the same role at Afferent before it was acquired by Merck & Co in 2016.

Mr. Butera's experience will be pivotal to the company's clinical development program, which "focuses on restoration of lost neurological function" by receptor activation in the brain, according to Anthony Ford, PhD, CEO of CuraSen.

More articles on devices:
'A dream come true': Dr. Jorge Chahla strives for success at Rush
New York hospital invests $2M in imaging system for spine, brain — 4 things to know
What Stryker's spine division stands to gain from 5 acquisitions 

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers